Meeting
2012 ASCO Annual Meeting
Genetic polymorphisms influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents.
Authors
Fabio Augusto Barros Schutz
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Fabio Augusto Barros Schutz , Kathryn P. Gray , Mark M Pomerantz , Michael B. Atkins , Michelle S. Hirsch , David F. McDermott , Megan Lampron , Andrew Percy , Gwo-Shu Mary Lee , Jonathan E. Rosenberg , Sabina Signoretti , Philip W. Kantoff , Matthew Freedman , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4635)
DOI
10.1200/jco.2012.30.15_suppl.4635
Abstract #
4635
Poster Bd #
9B
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Initial compared to deferred cytoreductive nephrectomy for metastatic kidney cancer and its association with improved survival in the targeted therapy era.
First Author: Liam Connor Macleod
Poster
2015 ASCO Annual Meeting
Pancreatic metastases from renal cell carcinoma: Prognostic relevance and outcome in patients treated with targeted agents.
First Author: Paolo Grassi
Poster
2014 ASCO Quality Care Symposium
Reporting on quality indicators in renal cell carcinoma: Proportion of metastatic patients who initially commence on full-dose targeted therapy.
First Author: Lori Wood
Poster
2014 Genitourinary Cancers Symposium
Liver metastases as predictors of outcome in renal cell carcinoma (RCC) patients (pts) treated with first-line sunitinib (SU) and sorafenib (SO).
First Author: Paolo Grassi